Phospholipase D inhibitors screening: Probing and evaluation of ancient and novel molecules

Yani Arhab, Karim Bessaa, Houda Abla, Meryem Aydin, Renaud Rahier, Arnaud Comte, Leyre Brizuela, Saïda Mebarek, Florent Perret, Mickaël Cherrier, et al.

International Journal of Biological Macromolecules

Phospholipase D inhibitors screening: probing and evaluation of ancient and novel molecules
--Manuscript Draft--

Manuscript Number:	IJBIOMAC-D-20-01603R2
Article Type:	Research Paper
Section/Category:	Proteins and Nucleic acids
Keywords:	phospholipase D, inhibitor, phosphatidic acid
Corresponding Author:	Alexandre Noiriel Univ Lyon, Université Lyon 1, Institut de Chimie et de Biochimie Moléculaires et Supramoléculaires (ICBMS), UMR 5246 CNRS, Métabolisme, Enzymes et Mécanismes Moléculaires (MEM2) Villeurbanne, FRANCE
First Author:	Yani Arhab
Order of Authors:	Yani Arhab
	Karim Bessaa
	Houda Abla
	Meryem Aydin
	Renaud Rahier
	Arnaud Comte
	Leyre Brizuela
	Saida Mebarek
	Florent Perret
	Mickael Cherrier
	Abdelkarim Abousalham
	Alexandre Noiriel
Abstract:	Phospholipase D (PLD) is a ubiquitous enzyme that cleaves the distal phosphoester bond of phospholipids generating phosphatidic acid (PA). In plants, PA is involved in numerous cell responses triggered by stress. Similarly, in mammals, PA is also a second messenger involved in tumorigenesis. PLD is nowadays considered as a therapeutic target and blocking its activity with specific inhibitors constitutes a promising strategy to treat cancers. Starting from already described PLD inhibitors, this study aims to investigate the effect of their structural modifications on the enzyme's activity, as well as identifying new potent inhibitors of eukaryotic PLDs. Being able to purify the plant PLD from Vigna unguiculata (VuPLD), we obtained a SAXS model of its structure. We then used a fluorescence-based test suitable for high-throughput screening to review the effect of eukaryotic PLD inhibitors described in the literature. In this regard, we found that only few molecules were in fact able to inhibit VuPLD and we confirmed that vanadate is the most potent of all with an IC50 around 58 μM. Moreover, the small-scale screening of a chemical library of 3,120 compounds allowed us to optimize the different screening's steps and paved the way towards the discovery of new potent inhibitors.
Suggested Reviewers:	Michael Frohman Michael.Frohman@Stonybrook.edu
	Johanna Mansfeld mansfeld@biochemtech.uni-halle.de Martin-Luther University Halle-Wittenberg, Institute of Biochemistry and Biotechnology, Kurt-Mothes-Str. 3, 06120 Halle (Germany).

	Sona Spandey
	spandey@danforthcenter.org
	Dr. Sona Pandey, Donald Danforth Plant Science Center, 975 N. Warson Rd., St. Louis, MO 63132 (USA)
	Dorothea Bartels
	dbartels@uni-bonn.de
	Pr. Dorothea Bartels, Institute of Molecular Physiology and Biotechnology of Planta (IMBIO), University of Bonn Kirschallee 1, 53115 Bonn (Germany)
Opposed Reviewers:	
Response to Reviewers:	

Phospholipase D inhibitors screening: probing and

evaluation of ancient and novel molecules

Yani Arhab [‡a], Karim Bessaa [‡a], Houda Abla [‡a], Meryem Aydin [‡], Renaud Rahier [‡], Arnaud

Comte [†], Leyre Brizuela [‡], Saïda Mebarek [‡], Florent Perret [+], Mickaël V. Cherrier[†], Abdelkarim

Abousalham [‡], and Alexandre Noiriel [‡]*

[‡] Univ Lyon, Université Lyon 1, Institut de Chimie et de Biochimie Moléculaires et Supramoléculaires (ICBMS), UMR 5246 CNRS, Métabolisme, Enzymes et Mécanismes Moléculaires (MEM^2), Bât Raulin, 43 Bd du 11 Novembre 1918, F-69622 Villeurbanne cedex, France.

[†] Univ Lyon, Université Lyon 1, Institut de Chimie et de Biochimie Moléculaires et Supramoléculaires (ICBMS), UMR 5246 CNRS, Chimiothèque, Bât Lederer, 43 Bd du 11 Novembre 1918, F-69622 Villeurbanne cedex, France.

[+] Univ Lyon, Université Lyon 1, Institut de Chimie et de Biochimie Moléculaires et Supramoléculaires (ICBMS), UMR 5246 CNRS, Chimie Supramoléculaire Appliquée (CSAp), Bât Raulin, 43 Bd du 11 Novembre 1918, F-69622 Villeurbanne cedex, France.

[†] Univ. Grenoble Alpes, CEA, CNRS, IBS, Metalloproteins, F-38000 Grenoble, France.

[a] These authors contributed equally to this work.

[*] To whom correspondence should be addressed

Keywords: phospholipase D, inhibitor, phosphatidic acid.

Abstract

Phospholipase D (PLD) is a ubiquitous enzyme that cleaves the distal phosphoester bond of phospholipids generating phosphatidic acid (PA). In plants, PA is involved in numerous cell responses triggered by stress. Similarly, in mammals, PA is also a second messenger involved in tumorigenesis. PLD is nowadays considered as a therapeutic target and blocking its activity with specific inhibitors constitutes a promising strategy to treat cancers. Starting from already described PLD inhibitors, this study aims to investigate the effect of their structural modifications on the enzyme's activity, as well as identifying new potent inhibitors of eukaryotic PLDs. Being able to purify the plant PLD from *Vigna unguiculata* (VuPLD)*,* we obtained a SAXS model of its structure. We then used a fluorescence-based test suitable for high-throughput screening to review the effect of eukaryotic PLD inhibitors described in the literature. In this regard, we found that only few molecules were in fact able to inhibit VuPLD and we confirmed that vanadate is the most potent of all with an IC_{50} around 58 µM. Moreover, the small-scale screening of a chemical library of 3,120 compounds allowed us to optimize the different screening's steps and paved the way towards the discovery of new potent inhibitors.

Introduction

Phospholipase D (PLD) (EC 3.1.4.4) is a diverse family of enzymes found in microbes, fungi, viruses, plants and animals [1]. In addition to its hydrolytic activity towards phospholipids releasing phosphatidic acid (PA) and a polar moiety, PLD catalyzes a transphosphatidylation reaction as well. This reaction occurs when a primary alcohol is used instead of water, making possible the synthesis of rarer phospholipids by exchanging the polar headgroup, as phosphatidylserine from the abundant phosphatidylcholine (PC) in the presence of serine.

Contrary to several bacterial PLDs, plant and mammalian PLDs share a common feature represented by a duplicated HKD motif that is involved in the catalytic reaction, there are then two classes of PLDs based on their primary structure: the HKD-containing and the non-HKD [2]. This latter family regroups well-used enzymes that belongs to the superfamily of PLC-like phosphodiesterases [3], such as the commercial PLD from *Streptomyces chromofuscus* [4] or the PLD from arachnids [5]. The HKD-containing PLD family belongs to the PLD superfamily and is mostly found in mammals as for example PLD1 and PLD2 in *Homo sapiens*, in plants as PLDα, in yeast with SPO14 [2,6,7], and in several microbes as the crystallized PLD from *Streptomyces sp*. strain PMF[8]. The hallmark of the PLD superfamily is the presence of the so-called HKD motif that is formed by a conserved His, Lys and Asp in a typical $HxKx_4D$ sequence that was recently refined [9]. In plants and mammals, the HKD motif is duplicated in the primary structure, and both motifs are thought to be closed in the tertiary structure to form the catalytic site at the interface of the bi-lobed enzyme [10–13].

Furthermore, one common mechanism of action defined as a two-step "ping-pong" reaction mechanism is conserved between plant and mammalian PLDs [2]. The interest in PLD as a drug target is due to the fact that PLDs are essential to intracellular and extracellular signaling. PLD

59   have been described to be involved in settings ranging from platelet activation to response to

60   cardiac ischemia, viral infections, neurodegenerative diseases, and in cancers. Therefore, human

61   PLD are a valid target for a variety of drug therapies [14].

62   Our work focuses on identifying potential new inhibitor of eukaryotic PLDs, especially the human

63   isoforms, by using a plant PLD as a model. Indeed, VuPLD shows an overall 19 % peptidic

64   sequence identity with human PLD1, which reaches 42 % and 69 % around the first and second

65   HKD motif, respectively. Thus, based on these elements, we hypothesized that an inhibitor

66   directed against the catalytic site of plant PLD would somehow be able to inhibit mammalian PLD

67   and *vice versa*. Previous works to screen inhibitors on mammalian PLD were weakened by the

68   difficulty to obtain sufficient amounts of enzyme for HTS of PLD inhibitors. This difficulty was

69   partially circumvented, either by the use of the atypical prokaryotic PLD enzyme from

70   *Streptomyces* for preliminary screenings [15], by using *in silico* methods [16], by virtual screening

71   [17], or other undisclosed conditions [18]. Recombinant plant PLDα is however easy to produce

72   and could be purified in one step [19]. Therefore, considering their similarities at multiple levels,

73   we assumed that a molecule capable of inhibiting plant PLDs could as well affect human PLDs.

74   This strategy could thus constitute an interesting and original approach to identify novel inhibitors

75   than using non-HKD PLDs as templates for the screening.

76   Only a few inhibitors of PLDs were described in the literature. N-acylethanolamines (NAEs) are

77   a class of potent lipids released from the membrane phospholipid N-acylphosphatidylethanolamine

78   (NAPE), and are found as endogenous constituents of desiccated seeds. The hydrolysis of NAPE

79   is catalyzed by a NAPE-specific PLD or PLD-like enzyme [20], but not by canonical PLD such as

80   plant PLDα. However, NAE is able to inhibit PLDα activity with an IC_{50} estimated at 0.15 µM as

81   for NAE (12:0) [21]. Applying NAE (12:0) improved seed desiccation tolerance via the inhibition

82 of PLDα, that led to the reduction of PA formation, PA being a key modulator of desiccation

83 sensitivity [22]. Likewise, lysophosphatidylethanolamine (LPE) was shown to be a specific

84 inhibitor of plant PLDs, that could act as a lipid-derived senescence retardant via the inhibition of

85 PLD [23]. As an example adding 10 µM of LPE (18:1) reduced by half the activity of PLD partially

86 purified from cabbage [23].

87 Similarly, the immunosuppressant ciclosporin at 5 µM was also shown to completely inhibit the

88 cabbage PLD activity [24], and so were alkylphosphate esters [25], octadecylphosphocholine

89 being the most efficient inhibitor of this class of molecules with an IC_{50} of 6.4 µM. However, these

90 molecules having a classical phosphoester bond they are substrate as well of PLD enzymes [26].

91 In fact, compared to PC, the canonical substrate tested in the same conditions, around 3% of the

92 specific activity was found when hexadecylphosphocholine was used [25]. Hexanal and its reduced

93 form hexanol have been shown to be effective PLD inhibitors in different subcellular fractions

94 from corn kernels, and PLD activity was inhibited from 50 to 70 % using 0.1 % of hexanal in *in*

95 *vitro* assays [27,28]. Volatile hexanal being a natural product of the catabolism of linoleic and

96 linolenic acid during senescence, it was used as a check-point for arresting membrane lipid

97 degradation in plants, and consequently enhances shelf-life of fruits as described in raspberry [29]

98 and in litchi [30]. PLD inhibition is used in banana when treated with hexanal, to thick the cell

99 wall and imped penetration of pathogenic spores [31]. Moreover, PLD in rice causes rancidity and

100 'stale flavor' in bran oil, and thus limits the rice bran usage [32], demonstrating the need for specific

101 plant PLD inhibitors.

102 As far as mammalian PLDs are concerned, several compounds were reported in literature. For

103 instance, fodrin [33] indirectly inhibits the PLD activity by decreasing the amount of

104 phosphatidylinositol (4,5)-bisphosphate (PIP2), a cofactor necessary for mammalian PLD activity.

105 However, this compound is not considered useful for research or clinical trials. Halopemide was

106 identified by HTS in 2007 as a modest inhibitor of PLD2 [18]. Several variants of halopemide

107 were then developed to exhibit a preferential selectivity towards either PLD1 or PLD2 [34]. *In*

108 *vitro*, halopemide has an IC_{50} of 220 and 310 nM for PLD1 and PLD2 respectively. Conversely,

109 VU0155069 is more selective towards PLD1, with an IC_{50} of 46 nM towards PLD1 compared to

110 933 nM towards PLD2 *in vitro*, and 11 nM and 1800 nM in cells respectively, whereas a

111 VU0364739 precursor is more selective towards PLD2 (IC_{50} of 140 nM *in vitro* and of 110 nM in

112 cells, compared to 5.1 µM *in vitro* and 1 µM in cells towards PLD1) [35]. Interestingly 5-fluoro-

113 2-indolyl des-chlorohalopemide (FIPI) which at approximately 25 nM induced a 50% loss of

114 activity independently on PLD1 and PLD2 [36] is thought to act on the catalytic site of both

115 isoforms PLD1 and PLD2. In the opposite VU0364739 which is selective of PLD2 [37] was

116 previously shown by computational modelling to use an allosteric site overlapping with the PH

117 domain to target its activity [38], but surface plasmon resonance experiments have demonstrated

118 that this family of inhibitors binds directly to the catalytic domain [11]. FIPI's IC_{50} on PLD from

119 *Streptomyces* strain PMF was reported to be around 100 nM, which is 4 to 6 times higher than the

120 values found on PLD1 and PLD2, demonstrating that some inhibitors directly block enzyme and

121 phospholipid vesicles substrate binding [15]. Last but not least, resveratrol, an antioxidant found

122 in red wine, was described to inhibit plant PLD [39], and human isoforms as well with an IC_{50}

123 around 61 µM [40].

124 In order to find the optimal conditions for the screening and to understand the best features of a

125 PLD inhibitor, we first characterized the purified enzyme VuPLD and described its physical shape

126 and biochemical structural properties. Then, we characterized the effect of already-known

127 inhibitors of eukaryotic PLD on VuPLD. Several types of inhibitors have been described in the

128 literature and could be basically divided into three classes. First, phosphate mimicking ions such

129 as vanadate [41] or tungstate that compete with the phosphate moiety of the phospholipid substrate.

130 Secondly natural products such as resveratrol [39] and ciclosporine [24], that are small organic

131 compounds supposedly protecting enterocyte mitochondria from oxidative stress. Finally,

132 halopemide and its derivatives that were specially designed for the two isoforms of mammalian

133 PLD with catalytic activity (PLD1 and PLD2). We then screened a chemical library of roughly

134 3,120 molecules of diverse origins. The optimization of a 6-step screen could now be used for

135 larger libraries.

136

Material and Methods

Reagents and material

139 1,2-Dimyristoyl-*sn*-glycero-3-phosphocholine (DMPC), choline oxidase from *Arthrobacter*

140 *globiformis*, horseradish peroxidase (type VI), bovine serum albumin (BSA), 8-hydroxyquinoline

141 (8HQ), resveratrol, ciclosporin, VU0285655, alcohols, hexanal, N-acylethanolamine, and mineral

142 salts: sodium vanadate, vanadate derivatives (oxytriethoxide, oxytripropoxide, oxytriisopropoxide,

143 tris(triphenylsiloxy)), tungstate and phosphate came from Sigma Aldrich-Fluka Chimie.

144 Halopemide, VU0359595, and FIPI were from Cayman Chemical. Palmitoyl-2-oleoyl-*sn*-glycero-3-

145 phosphocholine (POPC) and 1-palmitoyl-2-oleoyl-*sn*-glycero-3-phosphate (POPA) in chloroform

146 were purchased from Avanti Polar Lipids (Alabama, USA). Thin layer chromatography (TLC)

147 plates were purchased from Macherey-Nagel Gmbh & Co. Kg (Germany). Mammalian-PLDs

148 inhibitors halopemide and derivatives were from Cayman chemicals. Mineral salts: sodium

149 vanadate and its derivatives, tungstate and phosphate were dissolved in water. All PLD inhibitors

150 and compounds from the ICBMS chemical library were prepared in DMSO (DMSO levels used

151 in this study remained below 5%). Flat-bottom black 96-well microplates (Greiner bio-one) were

152 used for fluorescence measurements.

153

Purification of VuPLD

155 Recombinant VuPLD was produced in *Pichia pastoris* and purified as described previously [19].

156 Small aliquots were thawed and diluted before each experiment. A single batch was used for the

157 enzymatic characterization, and another for the screening of the chemical library. Protein

158 concentrations were determined using the Bradford's procedure [42], with Dye Reagent and BSA

159 as the standard.

160

Small angle X-ray scattering experiment

162 Data were collected at the ESRF beamline BM29 (Grenoble, France). VuPLD was concentrated

163 at 2.55 mg/mL in PIPES buffer 10 mM, pH 6.2, containing EDTA 0.1 mM and NaCl 200 mM.

164 Reconstruction of the overall shape of the VuPLD from X-ray scattering data was first achieved

165 by the *ab initio* modeling programs DAMMIN (20 models calculated) [43] or GASBOR (50

166 models calculated) [44], then models were averaged using DAMAVER [45]. Comparison of the

167 SAXS data and protein structure (PDB code : 6KZ9) was done using FoXS [46]. Protein molecular

168 mass was estimated from scattering intensities $I(0)$ using SAXSMoW2 software [47].

169

PLD activity measurement

171 *Chromogenic assay*

172 A detailed protocol of this assay has been recently published [48]. Briefly, 0.4 mM of DMPC in

173 SDS/Triton-X100 mixed micelles were incubated with pure PLD (0.7 to 0.9 µg/mL, final

174 concentration) in the presence or absence of inhibitors for 10 min at 30°C. The reaction was started

175 by the addition of 20 mM of $CaCl_2$, then blocked after 10 min by addition of 83.3 mM of EDTA,

176 and revealed by addition of peroxidase, choline oxidase, 2-hydroxy-3,5-dichlorobenzenesulfonate

177 and 4-aminoantipyrine. The PLD-generated choline was quantified with end point measurements

178 by recording the absorbance at 500 nm, based on a standard curve obtained with pure choline.

179

180 *Fluorescence-based assay*

181 The preparation of 8HQ / phospholipid/ detergent mixtures was adapted from [49] with minor

182 modifications to control the activation of the enzymes. To prepare the mixtures, 40 nmol of POPC

183 (266 µM, final concentration) were first dissolved in chloroform, then evaporated under a stream

184 of nitrogen. Subsequently, dried phospholipids were dispersed in a buffer containing 50 mM Tris-

185 HCl, pH 8.0, 1 mM Triton X-100, 0.7 mM SDS, 66 µM 8HQ, and 50 µM EDTA. The micellar

186 solution was vortexed for 30 s, sonicated for 10 min using a bath sonicator (Deltasonic type O11C,

187 Fécamp, France), then vortexed for an additional 30 s. One pmol of enzyme (VuPLD) was finally

188 added as well as the compounds to be tested. After a 10-minute incubation period at 30°C, the

189 reaction was triggered by adding 20 mM of $CaCl_2$. Fluorescence measurements were recorded at

190 30°C using a microtiter plate fluorescence reader (Tecan Infinite M200, Austria) at wavelengths

191 366 nm and 490 nm of excitation and emission, respectively. To monitor PLD activity, a baseline

192 of 4 kinetic cycles of 30 s was first recorded, after which 20 mM $CaCl_2$ were injected in each well

193 to trigger the PLD hydrolysis. Fluorescence intensities were then measured during a 1h-kinetic

194 cycle with interval shaking before each read. The PLD-generated PA was quantified by recording

195 the fluorescence in the same conditions as described above, based on a standard curve obtained

196 with pure POPA [49].

197

TLC analysis

199 The phospholipids were extracted with chloroform/methanol (2:1, v/v). The lower organic phase

200 was collected, dried, and subjected to TLC separation together with proper phospholipid standards.

201 TLC plates were developed in a solvent system using a mixture of chloroform/methanol/water

202 (65:25:5, v/v/v) as the eluent. Phospholipid spots were revealed by charring the plate after spraying

203 a mixture of 10 % copper sulfate and 10 % phosphoric acid in water and heating at 150°C for 5

204 min.

205

Statistical analysis

207 Statistically significant differences were determined by Brown-Forsyth and Welsh ANOVA test

208 using the computer program Prism (GraphPad Software). Results were considered significant

209 when $p < 0.05$ (*), highly significant when $p < 0.01$ (**), and extremely significant when $p < 0.001$

210 (***).

211

Results

213 **Modelization of VuPLD by SAXS experiment**

10

214 VuPLD was produced according to Arhab *et al.*[48]. The amount of homogenous VuPLD obtained

215 after purification was 1 mg per liter of yeast culture. The specific activity toward DMPC was 20

216 U/mg. Scattering measurement with synchrotron radiation were performed at pH 6.2 with 2.55

217 mg/mL of VuPLD. A typical SAXS profile of VuPLD is shown in Fig. 1A and a Kratky curve

218 displays a symmetric peak indicating that VuPLD is globular and correctly folded (Fig. 1B). From

219 scattering intensities I(0) a molecular mass of 89.1 kDa was calculated, which is in accordance

220 with a monomer of VuPLD as the theoretical molecular mass deduced from the amino acid

221 sequence is 91.5 kDa. The radius of gyration is 2.81 +/- 0.05 nm and D_{max} (maximum dimension)

222 is calculated to be 9.89 nm (Fig. 1C). The calculated model by DAMMIN shows a globular and

223 symmetric molecule with extended extremities and an ovoid shape (Fig. 1D). The program

224 GASBOR calculated a very similar model however this one is less symmetrical and displays a

225 larger base and a fine apical extremity (Fig. S1). The comparison of the collected SAXS data and

226 calculated scattering curve from the published structure of the PLD show a good correlation (Fig.

227 S2A) indicating that the protein adopts a similar conformation in the crystals and in solution. The

228 small differences observed could be due to small motion of the C2 domain.

229

Characterization of the salts effect on PLD activity

231 Ions such phosphate, tungstate and vanadate salts were already reported as potent inhibitors of

232 partially purified plant PLDs. We were able to confirm these results by measuring an IC_{50} for these

233 three ions on a pure VuPLD. Vanadate was the most potent of them with an IC_{50} of 58 µM and

234 being mostly able to totally inhibit the enzymatic activity at a concentration of 260 µM (Fig. 2A)

235 and was consequently used as a reference for HTS of PLD inhibitors. Likewise, tungstate was also

236 able to inhibit totally the PLD activity at a concentration of 2 mM, and harbored an IC_{50} value of

237   375 µM (Fig. 2C). Phosphate behaved in between, with an IC_{50} estimated to 125 µM but not being

238   able to totally abolish the activity, 25% of residual activity was quantified at 1 mM of phosphate

239   that is the maximal concentration usable in this test (Fig. 2B), as Ca^{2+} cofactor precipitates at higher

240   concentration of phosphate.

241   An unusual slight synergistic and inhibitory effect was observed when phosphate and vanadate

242   were incubated together (Fig. 2D). Indeed, when both molecules were incubated together at their

243   respective IC_{50}, only 15 % of residual activity was measured that was lower than the theoretical

244   25 % expected at these particular concentrations, suggesting the combined salts potentiate the PLD

245   inhibition.

246

247   **Vanadate derived compounds inhibitory effect on PLD activity**

248   Vanadate being the PLD inhibitor with the more potent inhibitory impacts, we decided to examine

249   the effects of the environment around this particular ion by testing diverse vanadate derivatives

250   such as vanadium oxytriethoxide, vanadium oxytripropoxide, vanadium oxytriisopropoxide and

251   tris(triphenylsiloxy) vanadium oxide, as all these molecules harbor different hydrocarbon chain

252   lengths and steric environment (Fig. S3). If vanadate took the place of the phosphate moiety of

253   phospholipid substrate in the active site, changes of alkyl chain length and steric environment

254   around vanadate would have been expected to modify its IC_{50}. However, even if the IC_{50} of

255   vanadate derivatives were lower than the one of vanadate (Fig. S4), no dramatic variation could

256   be observed amongst these four derivatives (Fig. 3). IC_{50} were ranging from 7 µM (vanadate

257   oxytriethoxide) to 15 µM (vanadate oxytriiosopropoxide).

258

259   **Alcohols inhibitory effect on PLD hydrolysis activity**

260 Historically, primary alcohols have been used as inhibitors of PLD hydrolysis activity. However,

261 one must state that it is not a proper inhibitory effect as the use of alcohol derives PLD activity

262 from hydrolysis *stricto sensu* toward the transphosphatidylation activity. In fact, alcohols can be

263 used as secondary substrate and therefore PLD can transfer the phosphatidyl group to a primary

264 alcohol to generate new phospholipids. The use of butan-1-ol is quite common to follow

265 mammalian PLD activity by detecting the production of phosphatidylbutanol. We consequently

266 tried to define which primary alcohol would be the best to avoid PLD-generated PA by testing the

267 primary alcohols from methanol to hexan-1-ol (Fig. 4).

268 As expected, methanol and ethanol were not efficient secondary substrates of VuPLD. For short-

269 chain alcohol the best candidate was butan-1-ol with an IC_{50} of 150 mM compared to propan-1-ol

270 which was more than twice less efficient with 320 mM. Pentan-1-ol had an IC_{50} of 60 mM which

271 is the best among all the alcohols tested. Finally, hexan-1-ol seemed not to be a proper secondary

272 substrate as the activity quickly falls at 20 mM probably indicating enzyme denaturation (Fig. 4A).

273 All secondary alcohols tested appeared not to be proper substrates as they displayed high IC_{50}, 160

274 mM for pentan-2-ol, 360 mM for butan-2-ol and propan-2-ol had no effect on PLD activity (Fig.

275 4A).

276 However, these values are based on the fluorimetric detection of PA (see Material & methods

277 section). A more convenient way to detect phosphatidylalcohols issued from the PLD-catalyzed

278 transphophatidylation reaction is to use TLC for phospholipids separation. As can be seen from

279 Fig. 4B, from all alcohols tested, the transphophatidylation products were qualitatively detected

280 only with methanol, ethanol, propan-1-ol and butan-1-ol.

281

282 **Effect of known mammalian PLD inhibitors on VuPLD**

13

283 Halopemide was shown previously to inhibit both human PLD1 and PLD2 isoforms, VU0359595

284 targets the PLD1 isoform with an IC_{50} calculated to be 3.7 nM, VU0285655 targets the PLD2

285 isoform with an IC_{50} calculated to be 635 nM. When tested on VuPLD, no inhibition could be

286 observed up to 10 µM (Fig. 5). The PLD activity was reduced down to 50 % when 100 µM of each

287 these three inhibitors were used independently.

288

Test of alleged plant PLD inhibitors

290 Amongst the molecules reported in literature to inhibit plant PLD activity we tested both

291 ciclosporin A and resveratrol on VuPLD using our fluorescence-based assay. In our hand, neither

292 ciclosporin A (Fig. 6A) nor resveratrol (Fig. 6B) were able to significantly affect VuPLD activity.

293 A slight 20% PLD inhibition could be observed using 2 mM of resveratrol, which is far from the

294 value reported by others where more than 90% of inhibition was measured with 130 µM of

295 resveratrol [39]. As far as ciclosporin A is concerned, no inhibition was detected until 100 µM

296 even if a quasi-total inhibition was previously reported for the PLD from cabbage using 5 µM of

297 this compound [24,39].

298 Similarly, neither NAE (Fig. 6C) nor hexanal (Fig. 6D) which have been demonstrated as efficient

299 inhibitors of castor bean [21] or raspberry [29] PLDs, respectively, displayed any inhibitory effect

300 on VuPLD.

301

Screening of new PLD inhibitors

303 Because of its sensitivity and ease of use, we aimed to validate the 8HQ-based assay suitability for

304 HTS of novel PLD inhibitors as a start. In order to do so, we calculated the Z'-factor, a statistical

305 parameter used to evaluate the quality and performance of an assay. This parameter is reflective

14

306 of both the assay signal dynamic range and the data variation associated with signal measurements

307 [50]. In light of former results showing sodium vanadate as the most potent inhibitor of VuPLD

308 (Fig. 2B), we consequently decided to use it as a reference and a positive control for the screening.

309 Briefly, confronting the variability of 30 values of PLD activity measured with either 100 μM of

310 vanadate or just 3 % DMSO, we obtained a calculated value of 0.803 for the Z'-score (Fig. 7A).

311 This value being comprised in the in the interval between 0.5 and 1.0 thus qualifies the 8HQ-based

312 test as "excellent" [50] for HTS of PLD inhibitors.

313 Moreover, as most of chemical library are DMSO solubilized, DMSO was shown only to have a

314 slight effect on PLD activity up to 5 % DMSO final concentration, but no statistical difference

315 compared from the control was observed when 5% DMSO final concentration was used (data not

316 shown).

317 We built a six-step protocol for the HTS of a PLD inhibitor (Fig. 7B). We consequently performed

318 a small-scale screening on the chemical library of our institute that is composed of 3,120

319 compounds from diverse origins. These molecules include quinolones, indoles, indolinones,

320 benzofurans, coumarins and flavonoids from chemistry and pharmaceutical laboratories.

321 A hit was considered every molecule capable to activate or inhibit PLD activity *in vitro* by more

322 than 50%. Out of 3,120 initial compounds, 227 molecules were found to reduce the PLD activity

323 and 53 to activate this activity (the others were found to have little or no effect at all). Because

324 some of the hits could be fluorescent molecules, or molecules with putative screen effect on the

325 8HQ probe, or molecules that could chelate the calcium ions for example, *id est* molecules that

326 could interfere with the fluorescent assay, we screened the putative 277 inhibitory molecules using

327 chromogenic assay which quantifies the free choline released by the PLD. After this step, 11

328 molecules were retained then further checked for their absence of effect on a PA standard curve

329   fluorescence. Finally, the 2 remaining compounds were tested on crude extract of *Pichia pastoris*

330   expressing VuPLD to avoid unspecific protein interaction. The last hit was confirmed against other

331   HKD-type PLDs like cabbage PLD [51] or peanut PLD [52]. Then, it was excluded after the last

332   step of this protocol as *de novo* synthesis of the molecule showed no effect at all and as several

333   contaminants were present in the initial batch of molecule used to make up the library.

334

Discussion

336   Using two different *ab initio* modelization programs SAXS data indicate that VuPLD is a globular

337   enzyme with elongated tops, thus the enzyme seems overall symmetrical with an ovoid shape.

338   These models do not allow the positioning of the regulatory C2 domain. The determination of the

339   overall shape of VuPLD is in accordance with the results obtained with cabbage PLDα2 in 2012

340   by others [53]. Both models of nearly the same length (809 residues for VuPLD compare to 812

341   for cabbage PLDα2) share 81.3% amino acid sequence identity and have a similar gyration radius,

342   but the D_{max} is lower in cabbage PLD (2.81 +/- 0.05 nm (this study) *vs* 2.89 +/- 0.01 nm [53])

343   indicating a slightly smaller enzyme. Also, the porod volume of VuPLD is more important

344   indicating a larger enzyme of 140.8 nm^3 *vs* 126.7 nm^3 for cabbage PLD [53]. These very slight

345   differences for such similar enzymes in terms of sequence might be explained by the fact that, even

346   if they are purified the same way, they are not recombinantly expressed in the same organism.

347   Specifically, cabbage PLD was expressed in *Escherichia coli* BL21 (DE3), contrary to VuPLD

348   that was expressed in yeast *Pichia pastoris* X33 cells which are known to glycosylate proteins.

349   The structure of PLDα1 from Arabidopsis that was recently solved [12] positioned the C2 domain

350   as a small protuberance interacting with the second HKD domain which is, however, not in

351   accordance with the ovoid shape with extended extremities of the VuPLD obtained in this work.

352 Nevertheless, the SAXS model of VuPLD (this work) and of PLD from cabbage [53], or crystal

353 structure of *Arabidopsis* PLD [12] are very close (Fig. S2B) and interchangeable, which makes of

354 VuPLD another PLD model, and specially a convenient tool to study PLD inhibition as this latest

355 protein could be recombinantly expressed and easily purified in one step [54].

356 To prove that VuPLD is a relevant model to study plant PLD inhibition, we started with the use of

357 substrate analogs, in particular, analogs of the phosphate head of phospholipid. Therefore, we

358 tested phosphate salt at first sight and structurally close chemicals like vanadate or tungstate. These

359 salts are known to modulate PLD activity and we show here that vanadate is the best of them with

360 the finest IC_{50}. Consequently, we tested vanadate derivatives that differ by their hydrophobic

361 properties. Indeed, vanadate and then vanadate oxytriethoxide, vanadate oxytripropoxide,

362 vanadate oxytriisopropoxide and tris(triphenylsiloxy) vanadium oxide are increasing hydrophobic

363 molecules. Among them, vanadate oxytriethoxide that only display ethane moieties around

364 vanadate salt is the best inhibitor. These results may suggest that the binding site of vanadate on

365 PLD was not influenced by the alkyl chain length and/or steric environment and has enough room

366 to allow the fixation of the different derivatives tested.

367 Another way to inhibit the hydrolase activity of PLDs is the use of alcohols, keeping in mind that

368 alcohols are not proper inhibitors but are just another secondary substrate competing with water to

369 induce a transphosphatidylation reaction. Here, we show that short-chained alcohols like methanol,

370 ethanol and to a lesser extent propan-1-ol do not affect the hydrolysis activity. Secondary alcohols

371 are also not substrates. The commonly used butan-1-ol is definitely the best primary alcohol

372 susceptible to generate a phosphatidylbutanol at a weak concentration. With other alcohols, no

373 transphosphatidylation products were visible on TLC plates, meaning that they are not proper

17

374 secondary substrates of PLD. But one has to notice the fact that they indeed reduce PLD activity.

375 As stated above for hexan-1-ol, propan-2-ol and pentan-1-ol probably induce enzyme denaturation.

376 Human PLD inhibitors do not show any inhibitory effect on plant PLD, even if these PLD [11]

377 [12] share a common and superposable active site (Fig. S5). These results ask questions about the

378 mechanism by which they inhibit human PLDs. We demonstrated recently that all PLDs share

379 common sequence motifs [9]. Among them a pocket constituted by two HKD motifs form the

380 catalytic site. But also, several similar sequences are found in all eukaryotic PLDs. Indeed, PLDs

381 are mostly differing by their regulatory motifs [9]. For example, human PLD bears a PX and PH

382 domain [2] whereas plant PLD bears a C2-domain responsible for the fixation of Ca^{2+} ions, a

383 mandatory activator of plant PLD [55]. However, the catalytic sites of *Arabidopsis* PLD [12] and

384 human PLD1 [13] share a common feature as globular fold with a funnel-shaped cavity leading to

385 the active site. Considering the localized relative sequence similarity between human PLD and

386 plant PLD, and considering that if human PLD inhibitors were targeting the catalytic site they

387 would have a similar effect on plant PLD, it is possible that human PLD inhibitors are targeting

388 (i) aminoacid sequences that do not exist in plant PLD or (ii) the regulatory domains and therefore

389 do not inhibit the catalytic activity of the enzyme but its capacity to bind its partners and cofactors.

390 The structure of the catalytic domains of human PLD1 and PLD2 that was recently published [11]

391 would surely help to explain the selectivity of several molecules thought or used as generic

392 inhibitors on plant and/or mammalian PLDs. As it was not been possible to solve the structure of

393 PLDα1 with FIPI [12], this compound is assumed to localized in the substrate-binding pocket of

394 the enzyme. However, our direct and continuous fluorescence based assay failed to display an

395 inhibitory effect on VuPLD, as no inhibition could be observed up to 100 μM (Fig. 5) and only an

396 apparent 29% reduction of activity was observed when 1 mM of FIPI was used (data not shown),

18

397 noting that such a high concentration would probably interfere with the fluorescence of the 8HQ

398 probe. These differences of FIPI effects could be explained by the nature of the plant PLDs used,

399 as some residues are dissimilar in this pocket among the plant PLDs, or by the nature of the test,

400 the activity being assayed in a direct and continuous manner in this work.

401 At the exception of vanadate that is still the more potent plant PLD inhibitor to our knowledge,

402 almost of all plant PLD inhibitors described in the literature failed to inhibit VuPLD, consequently

403 there is still a need for a specific plant PLD inhibitor or a generalist eukaryotic PLD inhibitors

404 acting both on plant and mammalian PLDs. Looking closely, it appears that the use of a purified

405 enzyme in this study is the major difference compared to all other papers published on this topic.

406 In this regard, it is possible that these compounds interfere with others enzymes used in the cascade

407 of choline quantification. On the other hand, in our case the use of an assay to directly measure the

408 PA released directly from PLD-catalysed hydrolysis, constitutes a significant advantage to

409 quantify PLD activity [49].

410 Indeed, this 8HQ-based assay was statistically validated with a Z' score of 0.803 indicating an

411 excellent test for HTS and demonstrating that vanadate should be used as a positive control for

412 forthcoming screenings. We consequently screened as a proof of concept a chemical library of

413 ~3,120 compounds. After six runs of enzymatic tests combining successively the advantages of

414 both fluorescent and chromogenic assays to avoid false positives, no hit could unfortunately be

415 retained as the unique potential candidate appeared to be a contaminant. In the future, combining

416 the two PLD enzymatic assays with their specific strengths and weaknesses, their distinct and

417 alternative properties, larger libraries could be screened to identify and validate new PLD

418 inhibitors.

419

420 In conclusion, this work highlights (i) the necessity for a novel universal inhibitor potentially

421 targeting the catalytic site of PLDs, (ii) the potential of a purified plant PLD to screen PLD

422 inhibitors and (iii) the need to screen larger chemical libraries to find new inhibitory molecules.

423

424

425

426 Author Information

427 **Corresponding Author**

428 *To whom correspondence should be addressed

429 Tel: +33 4 27 46 57 31

430 E-mail address: alexandre.noiriel@univ-lyon1.fr

431

432 **Author Contributions**

433 YA and MVC performed SAXS and modeling experiments. AC and FP contributed to compound

434 design and synthesis. YA, KB, HA, MA, RR performed biochemical assays. LB, SM, AA and AN

435 devised the project and the main conceptual ideas. AN was in charge of funding acquisition. All

436 authors contributed to data interpretation. The manuscript was written from contributions by all

437 the authors. All the authors have given approval to the final version of the manuscript.

438

Acknowledgments

Abbreviations

8-Hydroxyquinoline (8HQ), high-throughput screening (HTS), lysophosphatidylethanolamine (LPE), N-acylethanolamines (NAE), N-acylphosphatidylethanolamine (NAPE), phosphatidic acid (PA), phospholipase D (PLD), palmitoyl-2-oleoyl-*sn*-glycero-3-phosphocholine (POPC).

References

[1]   S.M. Hammond, Y.M. Altshuller, T.C. Sung, S.A. Rudge, K. Rose, J. Engebrecht, A.J. Morris, M.A. Frohman, Human ADP-ribosylation factor-activated phosphatidylcholine-specific phospholipase D defines a new and highly conserved gene family, J. Biol. Chem. 270 (1995) 29640–29643.

[2]   P.E. Selvy, R.R. Lavieri, C.W. Lindsley, H.A. Brown, Phospholipase D: enzymology, functionality, and chemical modulation, Chem. Rev. 111 (2011) 6064–6119. https://doi.org/10.1021/cr200296t.

[3] A. Marchler-Bauer, Y. Bo, L. Han, J. He, C.J. Lanczycki, S. Lu, F. Chitsaz, M.K. Derbyshire, R.C. Geer, N.R. Gonzales, M. Gwadz, D.I. Hurwitz, F. Lu, G.H. Marchler, J.S. Song, N. Thanki, Z. Wang, R.A. Yamashita, D. Zhang, C. Zheng, L.Y. Geer, S.H. Bryant, CDD/SPARCLE: functional classification of proteins via subfamily domain architectures, Nucleic Acids Res. 45 (2017) D200–D203. https://doi.org/10.1093/nar/gkw1129.

[4] S. Imamura, Y. Horiuti, Purification of Streptomyces chromofuscus phospholipase D by hydrophobic affinity chromatography on palmitoyl cellulose, J. Biochem. (Tokyo). 85 (1979) 79–95.

[5] S. Lee, K.R. Lynch, Brown recluse spider (Loxosceles reclusa) venom phospholipase D (PLD) generates lysophosphatidic acid (LPA), Biochem. J. 391 (2005) 317–323. https://doi.org/10.1042/BJ20050043.

[6] S.A. Rudge, J. Engebrecht, Regulation and function of PLDs in yeast, Biochim. Biophys. Acta. 1439 (1999) 167–174.

[7] K. Rose, S.A. Rudge, M.A. Frohman, A.J. Morris, J. Engebrecht, Phospholipase D signaling is essential for meiosis, Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 12151–12155.

[8] I. Leiros, F. Secundo, C. Zambonelli, S. Servi, E. Hough, The first crystal structure of a phospholipase D, Struct. Lond. Engl. 1993. 8 (2000) 655–667.

[9] Y. Arhab, A. Abousalham, A. Noiriel, Plant phospholipase D mining unravels new conserved residues important for catalytic activity, Biochim. Biophys. Acta Mol. Cell Biol. Lipids. 1864 (2019) 688–703. https://doi.org/10.1016/j.bbalip.2019.01.008.

[10] C.P. Ponting, I.D. Kerr, A novel family of phospholipase D homologues that includes phospholipid synthases and putative endonucleases: identification of duplicated repeats and potential active site residues, Protein Sci. Publ. Protein Soc. 5 (1996) 914–922. https://doi.org/10.1002/pro.5560050513.

[11] C.M. Metrick, E.A. Peterson, J.C. Santoro, I.J. Enyedy, P. Murugan, T. Chen, K. Michelsen, M. Cullivan, K.A. Spilker, P.R. Kumar, T.L. May-Dracka, J.V. Chodaparambil, Human PLD structures enable drug design and characterization of isoenzyme selectivity, Nat. Chem. Biol. (2020). https://doi.org/10.1038/s41589-019-0458-4.

[12] J. Li, F. Yu, H. Guo, R. Xiong, W. Zhang, F. He, M. Zhang, P. Zhang, Crystal structure of plant PLDα1 reveals catalytic and regulatory mechanisms of eukaryotic phospholipase D, Cell Res. (2019). https://doi.org/10.1038/s41422-019-0244-6.

[13] F.Z. Bowling, C.M. Salazar, J.A. Bell, T.S. Huq, M.A. Frohman, M.V. Airola, Crystal structure of human PLD1 provides insight into activation by PI(4,5)P2 and RhoA, Nat. Chem. Biol. 16 (2020) 400–407. https://doi.org/10.1038/s41589-020-0499-8.

[14] M.I. McDermott, Y. Wang, M.J.O. Wakelam, V.A. Bankaitis, Mammalian phospholipase D: Function, and therapeutics, Prog. Lipid Res. (2019) 101018. https://doi.org/10.1016/j.plipres.2019.101018.

[15] A. Kulkarni, P. Quang, V. Curry, R. Keyes, W. Zhou, H. Cho, J. Baffoe, B. Török, K. Stieglitz, 1,3-disubstituted-4-aminopyrazolo [3, 4-d] pyrimidines, a new class of potent inhibitors for phospholipase D, Chem. Biol. Drug Des. 84 (2014) 270–281. https://doi.org/10.1111/cbdd.12319.

[16] H. Djakpa, A. Kulkarni, S. Barrows-Murphy, G. Miller, W. Zhou, H. Cho, B. Török, K. Stieglitz, Identifying New Drug Targets for Potent Phospholipase D Inhibitors: Combining Sequence Alignment, Molecular Docking, and Enzyme Activity/Binding Assays, Chem. Biol. Drug Des. 87 (2016) 714–729. https://doi.org/10.1111/cbdd.12705.

[17] D.K. Behera, P.M. Behera, L. Acharya, A. Dixit, Pharmacophore modelling, virtual screening and molecular docking studies on PLD1 inhibitors, SAR QSAR Environ. Res. 28 (2017) 991–1009. https://doi.org/10.1080/1062936X.2017.1393774.

[18] L. Monovich, B. Mugrage, E. Quadros, K. Toscano, R. Tommasi, S. LaVoie, E. Liu, Z. Du, D. LaSala, W. Boyar, P. Steed, Optimization of halopemide for phospholipase D2 inhibition, Bioorg. Med. Chem. Lett. 17 (2007) 2310–2311. https://doi.org/10.1016/j.bmcl.2007.01.059.

[19] Y. Ben Ali, F. Carriere, A. Abousalham, High-level constitutive expression in Pichia pastoris and one-step purification of phospholipase D from cowpea (Vigna unguiculata L. Walp), Protein Expr Purif. 51 (2007) 162–9. https://doi.org/10.1016/j.pep.2006.07.018.

[20] Z. Hussain, T. Uyama, K. Tsuboi, N. Ueda, Mammalian enzymes responsible for the biosynthesis of N-acylethanolamines, Biochim. Biophys. Acta. 1862 (2017) 1546–1561. https://doi.org/10.1016/j.bbalip.2017.08.006.

[21] S.L. Austin-Brown, K.D. Chapman, Inhibition of phospholipase D alpha by N-acylethanolamines, Plant Physiol. 129 (2002) 1892–1898. https://doi.org/10.1104/pp.001974.

[22] H. Chen, X. Yu, X. Zhang, L. Yang, X. Huang, J. Zhang, H.W. Pritchard, W. Li, Phospholipase Dα1-mediated phosphatidic acid change is a key determinant of desiccation-induced viability loss in seeds, Plant Cell Environ. 41 (2018) 50–63. https://doi.org/10.1111/pce.12925.

[23] S.B. Ryu, B.H. Karlsson, M. Ozgen, J.P. Palta, Inhibition of phospholipase D by lysophosphatidylethanolamine, a lipid-derived senescence retardant, Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 12717–12721.

[24] M. Madesh, K.A. Balasubramanian, Cyclosporin A inhibits oxidant and calcium stimulated phospholipase D activity in the rat intestinal mitochondria, Biochim. Biophys. Acta. 1389 (1998) 206–212.

[25] N. Dittrich, G. Nössner, B. Kutscher, R. Ulbrich-Hofmann, Alkylphosphate esters as inhibitors of phospholipase D, J. Enzym. Inhib. 11 (1996) 67–75.

[26] Y. Ohno, M. Okazaki, I. Hara, Studies on the activity of phospholipase D with alkyl phosphorylcholines, Biochem. Cell Biol. Biochim. Biol. Cell. 68 (1990) 376–379.

[27] G. Paliyath, R.G. Pinhero, R.Y. Yada, D.P. Murr, Effect of processing conditions on phospholipase D activity of corn kernel subcellular fractions, J. Agric. Food Chem. 47 (1999) 2579–2588.

[28] K. Tiwari, G. Paliyath, Microarray analysis of ripening-regulated gene expression and its modulation by 1-MCP and hexanal, Plant Physiol. Biochem. PPB. 49 (2011) 329–340. https://doi.org/10.1016/j.plaphy.2011.01.007.

[29] W.E. Kayal, G. Paliyath, J.A. Sullivan, J. Subramanian, Phospholipase D inhibition by hexanal is associated with calcium signal transduction events in raspberry, Hortic. Res. 4 (2017) 17042. https://doi.org/10.1038/hortres.2017.42.

[30] B. Bhushan, S. Kumar, M.K. Mahawar, K. Jalgaonkar, A.S. Dukare, B. Bibwe, V.S. Meena, N. Negi, R.K. Narwal, A. Pal, Nullifying phosphatidic acid effect and controlling phospholipase D associated browning in litchi pericarp through combinatorial application of hexanal and inositol, Sci. Rep. 9 (2019) 2402. https://doi.org/10.1038/s41598-019-38694-5.

[31] D. Dhakshinamoorthy, S. Sundaresan, A. Iyadurai, K.S. Subramanian, G.J. Janavi, G. Paliyath, J. Subramanian, Hexanal Vapor Induced Resistance against Major Postharvest Pathogens of Banana (Musa acuminata L.), Plant Pathol. J. 36 (2020) 133–147. https://doi.org/10.5423/PPJ.OA.03.2019.0072.

554 [32] A. Kaur, K. Neelam, K. Kaur, A. Kitazumi, B.G. de Los Reyes, K. Singh, Novel allelic
555   variation in the Phospholipase D alpha1 gene (OsPLDα1) of wild Oryza species implies to
556   its low expression in rice bran, Sci. Rep. 10 (2020) 6571. https://doi.org/10.1038/s41598-
557   020-62649-w.

558 [33] S. Lukowski, J.P. Mira, A. Zachowski, B. Geny, Fodrin inhibits phospholipases A2, C, and
559   D by decreasing polyphosphoinositide cell content, Biochem. Biophys. Res. Commun. 248
560   (1998) 278–284. https://doi.org/10.1006/bbrc.1998.8942.

561 [34] J.A. Lewis, S.A. Scott, R. Lavieri, J.R. Buck, P.E. Selvy, S.L. Stoops, M.D. Armstrong, H.A.
562   Brown, C.W. Lindsley, Design and synthesis of isoform-selective phospholipase D (PLD)
563   inhibitors. Part I: Impact of alternative halogenated privileged structures for PLD1
564   specificity, Bioorg. Med. Chem. Lett. 19 (2009) 1916–1920.
565   https://doi.org/10.1016/j.bmcl.2009.02.057.

566 [35] S.A. Scott, P.E. Selvy, J.R. Buck, H.P. Cho, T.L. Criswell, A.L. Thomas, M.D. Armstrong,
567   C.L. Arteaga, C.W. Lindsley, H.A. Brown, Design of isoform-selective phospholipase D
568   inhibitors that modulate cancer cell invasiveness, Nat. Chem. Biol. 5 (2009) 108–117.
569   https://doi.org/10.1038/nchembio.140.

570 [36] W. Su, O. Yeku, S. Olepu, A. Genna, J.-S. Park, H. Ren, G. Du, M.H. Gelb, A.J. Morris,
571   M.A. Frohman, 5-Fluoro-2-indolyl des-chlorohalopemide (FIPI), a phospholipase D
572   pharmacological inhibitor that alters cell spreading and inhibits chemotaxis, Mol. Pharmacol.
573   75 (2009) 437–446. https://doi.org/10.1124/mol.108.053298.

574 [37] R.R. Lavieri, S.A. Scott, P.E. Selvy, K. Kim, S. Jadhav, R.D. Morrison, J.S. Daniels, H.A.
575   Brown, C.W. Lindsley, Design, synthesis, and biological evaluation of halogenated N-(2-(4-
576   oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)ethyl)benzamides: discovery of an isoform-
577   selective small molecule phospholipase D2 inhibitor, J. Med. Chem. 53 (2010) 6706–6719.
578   https://doi.org/10.1021/jm100814g.

579 [38] R. Ganesan, M. Mahankali, G. Alter, J. Gomez-Cambronero, Two sites of action for PLD2
580   inhibitors: The enzyme catalytic center and an allosteric, phosphoinositide biding pocket,
581   Biochim. Biophys. Acta. 1851 (2015) 261–272.
582   https://doi.org/10.1016/j.bbalip.2014.12.007.

583 [39] S. Majd, E.C. Yusko, A.D. MacBriar, J. Yang, M. Mayer, Gramicidin pores report the activity
584   of membrane-active enzymes, J. Am. Chem. Soc. 131 (2009) 16119–16126.
585   https://doi.org/10.1021/ja904072s.

586 [40] J. Tou, C. Urbizo, Resveratrol inhibits the formation of phosphatidic acid and diglyceride in
587   chemotactic peptide- or phorbol ester-stimulated human neutrophils, Cell. Signal. 13 (2001)
588   191–197. https://doi.org/10.1016/s0898-6568(01)00137-1.

589 [41] L. Li, N. Fleming, Aluminum fluoride inhibition of cabbage phospholipase D by a phosphate-
590   mimicking mechanism, FEBS Lett. 461 (1999) 1–5. https://doi.org/10.1016/s0014-
591   5793(99)01414-3.

592 [42] M.M. Bradford, A rapid and sensitive method for the quantitation of microgram quantities of
593   protein utilizing the principle of protein-dye binding, Anal Biochem. 72 (1976) 248–54.

594 [43] D.I. Svergun, Restoring low resolution structure of biological macromolecules from solution
595   scattering using simulated annealing, Biophys. J. 76 (1999) 2879–2886.
596   https://doi.org/10.1016/S0006-3495(99)77443-6.

597 [44] D.I. Svergun, M.V. Petoukhov, M.H. Koch, Determination of domain structure of proteins
598   from X-ray solution scattering, Biophys. J. 80 (2001) 2946–2953.
599   https://doi.org/10.1016/S0006-3495(01)76260-1.

600   [45] V.V. Volkov, Svergun, D.I., Uniqueness of ab initio shape determination in small-angle
601   scattering, J. Appl. Crystallogr. (2003) 860–864.

602   [46] D. Schneidman-Duhovny, M. Hammel, J.A. Tainer, A. Sali, FoXS, FoXSDock and
603   MultiFoXS: Single-state and multi-state structural modeling of proteins and their complexes
604   based on SAXS profiles, Nucleic Acids Res. 44 (2016) W424-429.
605   https://doi.org/10.1093/nar/gkw389.

606   [47] V. Piiadov, E. Ares de Araújo, M. Oliveira Neto, A.F. Craievich, I. Polikarpov, SAXSMoW
607   2.0: Online calculator of the molecular weight of proteins in dilute solution from experimental
608   SAXS data measured on a relative scale, Protein Sci. Publ. Protein Soc. 28 (2019) 454–463.
609   https://doi.org/10.1002/pro.3528.

610   [48] Y. Arhab, R. Rahier, A. Noiriel, M.V. Cherrier, A. Abousalham, Expression and Purification
611   of Recombinant Vigna unguiculata Phospholipase D in Pichia pastoris for Structural Studies,
612   in: G. Sandoval (Ed.), Lipases Phospholipases, Springer New York, New York, NY, 2018:
613   pp. 191–201. https://doi.org/10.1007/978-1-4939-8672-9_10.

614   [49] R. Rahier, A. Noiriel, A. Abousalham, Development of a Direct and Continuous
615   Phospholipase D Assay Based on the Chelation-Enhanced Fluorescence Property of 8-
616   Hydroxyquinoline, Anal Chem. 88 (2016) 666–74.
617   https://doi.org/10.1021/acs.analchem.5b02332.

618   [50] J. Zhang, T. Chung, K. Oldenburg, A Simple Statistical Parameter for Use in Evaluation and
619   Validation of High Throughput Screening Assays, J. Biomol. Screen. 4 (1999) 67–73.
620   https://doi.org/10.1177/108705719900400206.

621   [51] H. Sato, T. Watanabe, Y. Sagane, Y. Nakazawa, K. Takano, Purification and Characterization
622   of Phospholipase D from Cabbage Leaves., Food Sci. Technol. Res. 6 (2000) 29–33.
623   https://doi.org/10.3136/fstr.6.29.

624   [52] Y. Nakazawa, H. Sato, M. Uchino, K. Takano, Purification, characterization and cloning of
625   phospholipase D from peanut seeds, Protein J. 25 (2006) 212–223.
626   https://doi.org/10.1007/s10930-006-9004-9.

627   [53] S. Stumpe, S. König, R. Ulbrich-Hofmann, Insights into the structure of plant α-type
628   phospholipase D: Structure of plant phospholipase D, FEBS J. 274 (2007) 2630–2640.
629   https://doi.org/10.1111/j.1742-4658.2007.05798.x.

630   [54] Arhab, Y, Rahier, R, Noiriel, A, Cherrier, MV, Abousalham, A, Expression and Purification
631   of Recombinant Vigna unguiculata Phospholipase D in Pichia pastoris for Structural Studies,
632   Methods Mol. Biol. Press. (2018) In press.

633   [55] K. Pappan, X. Wang, Molecular and biochemical properties and physiological roles of plant
634   phospholipase D, Biochim. Biophys. Acta. 1439 (1999) 151–166.

635

Fig. 1: SAXS modelization of VuPLD.
A) Diffusion curve. B) Kratky curve. C) Distance distribution function P(r) calculated from X-ray scattering data. D) *Ab initio* low-resolution structure model of VuPLD calculated from the SAXS pattern and the program DAMMIN. Model is shown in two different views obtained by 90° rotation around the y-axis.

Fig. 2: Inhibitory effect of different salts on purified VuPLD.
The PLD activity was measured with the fluorimetric assay in triplicates and with increasing concentrations of sodium vanadate (A), sodium tungstate (B) or sodium phosphate (C). D) PLD relative activity incubated with 0 μM (circle ●), 25 μM (square ■), 50 μM (triangle ▲) or 100 μM (cross ✳) of phosphate at different concentrations of vanadate. Relative PLD activities were calculated relatively to the enzyme incubated in the absence of effector set at 100 %. Values are the mean ± SD obtained from three independent assays.

Fig. 3: Inhibitory effect of different vanadate derivatives on purified VuPLD.
The activity was measured with the chromogenic assay in triplicates with increasing concentrations of vanadate (circle ●), vanadate oxytriethoxide (square ■), vanadate oxytripropoxide (triangle ▲), vanadate oxytriisopropoxide (cross ⁎) or vanadate tris(triphenylsiloxy) (diamond◆). Values are the mean ± SD obtained from three independent chromogenic assays.

Fig. 4: Effect of different alcohols on purified VuPLD.
A) The activity was measured in triplicates with increasing concentrations of methanol (black dash—), ethanol (square■), propan-1-ol (white triangle △), propan-2-ol (black triangle ▲), butan-1-ol (white diamond ◇), butan-2-ol (black diamond ◆), pentan-1-ol (white circle○), pentan-2-ol (black circle●) and hexanol (cross ✳). Relative activities were calculated relatively to the enzyme incubated in the absence of effector (100%). Values are the mean ± SD obtained from three independent fluorimetric assays. B) TLC analysis of the VuPLD catalyzed transphosphatidylation reaction products obtained from (A). Lipids were extracted, developed, and revealed as described in the experimental section. POPA, phosphatidylbutanol (P-But) and phosphatidylethanol (P-Eth) were run as standard reaction products,

Fig. 5: Inhibitory effect of known inhibitors of human PLD on purified plant VuPLD.

The activity was measured in triplicates with increasing concentrations of halopemide (black), VU0359595 (dark grey), VU0285655 (light grey), FIPI (white). Relative activities are calculated relatively to the enzyme incubated with 0 μM of effector (100%). Values are the mean ± SD obtained from three independent fluorimetric assays. ** P<0.01, *** P<0.001 (*vs* untreated).

Fig. 6: Inhibitory effect of alleged inhibitors of plant PLD.
PLD described inhibitors, ciclosporin A (A), resveratrol (B), NAE C12:0 (C) and hexanal (D) were tested at different concentrations from 1 μM to 1 mM. Relative activities are then calculated relatively to the enzyme incubated in the absence of effector (100%). Values are the mean ± SD obtained from three independent fluorimetric assays. *P<0.05, **P<0.01 (*vs* untreated).

Fig. 7: HTS screening of a new PLD inhibitor.
PLD activity was measured in the presence or absence of 100 μM of vanadate in order to establish the variation of the assay and the calculation of the Z' score. Multiple repeats (n=30) were realized with (circles) or without effector (squares). B) Seven-step workflow for the identification of novel PLD inhibitors.

Fig. S1: SAXS modelization of VuPLD.
Ab initio low-resolution structure model of VuPLD calculated from the SAXS pattern and the program GASBOR. Model is shown in two different views obtained by 90° rotation around the y-axis

Fig. S2: Analysis of SAXS data of VuPLD.
A) Comparison of the experimental scattering data (gray circles) with the calculated scattering profile from PLD structure.
B) Experimental SAXS curve of VuPLD (grey dots) compared to the theoretical SAXS curve of PLDα1 (black line) from Arabidopsis (PDB code 6KZ9).

Vanadate   Vanadate triethoxide   Vanadate tripropoxide

Vanadate triisopropoxide   Vanadate tris(triphenylsiloxy)

Fig. S3: Chemical structures of vanadate and its derivatives

Fig. S4: Inhibition of purified plant PLD by vanadate.
The activity was measured in triplicates with increasing concentrations of vanadate. Values are the mean ± SD obtained from three independent chromogenic assays.

N-term HKD motif   C-term HKD motif

Lys

His

His

Lys

Fig. S5: Comparison of plant and mammalian PLD catalytic pockets.
Both HKD motifs are displayed in blue (human PLD, 6OHR) and red (plant PLD, 6KZ9) according to [9].
Histidyl and lysyl catalytic residues are represented (sticks) and annotated. Structure superposition was done
using Pymol 2.3.2..

Author Statement

YA and MVC performed SAXS and modeling experiments. AC and FP contributed to compound design and synthesis. YA, KB, HA, MA, RR performed biochemical assays. LB, SM, AA and AN devised the project and the main conceptual ideas. AN was in charge of funding acquisition. All authors contributed to data interpretation. The manuscript was written from contributions by all the authors. All the authors have given approval to the final version of the manuscript.